Answers are grounded in this paper and cite their sources.
The tumor-node-metastasis (TNM) staging system of the American Joint Cancer Committee (AJCC)/Union for International Cancer Control (UICC) is a tool originally conceived for description of disease extent, aimed at providing prognostic information and making useful “post hoc” comparisons possible between different centers/series and/or therapeutic strategies. Nevertheless, in everyday clinical practice, it is frequently (and inappropriately) employed “upfront” in choosing primary and/or complementary treatment(s) for a given patient. To correctly assign outcomes categories and possibly (de-) escalate treatment accordingly, a staging system should identify distinct prognostic stratifications that must be internally homogeneous, while at the same time differing from one another. Moreover, when aiming towards more finely-tuned staging accuracy, TNM should remain relatively simple, user friendly, and reproducible.
No takes yet. Share an insight, caveat, or question.
Piazza et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: